Building Resilience in Cell Therapy Supply Chains: Ensuring Timely and Safe Delivery
Executive Summary In the fast-paced world of cell and gene therapies, building a resilient...
read DetailsCell & Gene
Guiding the most innovative cell and gene therapies through the complexities of cold chain approval
LET'S TALKCell and gene therapies like CAR-T are transforming healthcare‑providing innovative treatment modalities that hold great promise for previously untreatable diseases, including orphan diseases and genetic conditions. By leveraging the patient’s own biological materials, these individualized therapies can prove life-altering.
Cell and gene therapies involve the most complex supply chain to validate in the biopharma industry, especially for a fully closed-loop autologous CAR-T cell supply chain that starts and ends with the patient. From tight timelines, to rigorous temperature requirements (whether cryogenic, deep frozen, or refrigerated), to the use of fragile vials for storage and innovative reusable packaging, the supply chain for personalized medicines is highly complex.
Modality Solutions is uniquely qualified to optimize the cold chain and facilitate regulatory review and approval for cell and gene therapies like CAR-T and other individualized regenerative medicines. We leverage our deep knowledge of these complex therapeutics, unrivaled cold chain expertise, and a proven track record of helping biopharmaceutical companies overcome a complicated regulatory landscape to bring cell and gene therapies to market successfully.
From regulatory filing support, to customized engineering consulting, cold chain optimization, and rigorous transport simulation testing, Modality Solutions provides the full range of capabilities to guide your cell and gene therapy candidate through review and commercial approval.
Atara Biotherapeutics Case Study:
To gain approval for its new CAR-T Cell Therapy, Atara Biotherapeutics needed to demonstrate an ability to safely transport a fragile therapeutic with deep-frozen temperature requirements...
View the case study nowWe help prepare you for a successful regulatory filing every step of the way—assessing your cold chain, drug stability, packaging, and third-party logistics qualifications; developing a validation master plan; conducting transport simulation testing; and preparing your team for the CTD submission and pre-approval inspection.
Learn MoreWhether you need turnkey support or you want to augment your in-house resources, our customizable Transport Simulation Solutions can deliver the robust data regulators expect during your drug’s review and approval. We assess transport risks, develop validation master plans, and rigorously test drug formulations and packaging for the five hazards that can occur in transport—concurrently and at the edges of the supply chain’s operating space—through our ISO-certified Advantage Transport Simulation Laboratory™.
Learn MoreWhen you’re preparing for a new filing, responding to an Information Request, or looking to improve the supply chain for a commercial product, our Cold Chain Consulting and Cold Chain Engineering™ services are invaluable. Our cold chain consultants and experts draw on their extensive experience to help you overcome complex supply chain challenges, reduce risk, and meet regulatory requirements at every phase.
Learn MoreModality Solutions can conduct rigorous, comprehensive testing of your therapeutic against a wide range of ASTM and ISTA standards at our independent Advantage Transport Simulation Laboratory™ or a third-party lab—ranging from plunger movement studies to confirm sterility and efficacy, to drug-device functionality testing, and many other applications.
Learn MoreWe help enhance your cold chain’s performance for therapeutics that have already reached the commercial market—reducing shipping and packaging costs while ensuring your drug product remains protected in transit. From package design engineering and evaluation, to packaging selection support, to logistics network design, our Cold Chain Optimization Solutions ensure your supply chain is up to the challenge of transporting fragile or controlled-temperature therapies.
Learn MoreCell & Gene Therapy will grow to:
$35.4 B
The cell and gene therapy market is forecasted to grow to $35.4 billion by 2026, representing a compound annual growth rate of 22 percent.
Cold Chain Engineering
Learn MoreTransport Simulation Lab
Learn MoreAI-Driven Cold Chain Optimization
Learn MoreEmergency Response to Regulatory Inquiries
Learn MoreExecutive Summary In the fast-paced world of cell and gene therapies, building a resilient...
read DetailsCell & Gene
Monoclonal Antibodies: Monoclonal antibodies (mAbs) are clones of the antibodies that our body secretes...
read DetailsCell & Gene
Modality Solutions is paving the way for the future of pharmaceutical transportation testing. The...
read DetailsCell & Gene